Now Available On Demand
Randomized, controlled clinical trials (RCTs) are the FDA-preferred approach for registrational studies in new drug and biologics development. However, there are circumstances in oncology where a single-arm trial can expedite the development of new treatments for oncology indications, reduce time to product approval and patient access, and demonstrate clinical benefit of novel product(s) on fewer patients.
Join Veristat experts during a live webinar as they discuss single-arm oncology registrational studies, success stories and lessons learned in:
- Identifying unmet medical needs that may allow for a single-arm registrational study
- Developing a single-arm study design for registration
- Determining a regulatory strategy
Meet the Speakers

Robin Bliss, PhD
Vice President, Strategic Consulting, Veristat

Debora Manning, MPH
Strategic Consulting Fellow, Biostatistician, Veristat

Toni Marie Nearing, BS
Principal Regulatory Strategist, Veristat